Analysed ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) News Sources
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
04-06-2026
marketbeat.com
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
06-08-2026
yahoo.com
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
27-10-2026
yahoo.com
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
27-10-2026
yahoo.com
Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?
27-10-2026
stocktwits.com
Aclaris Therapeutics Reports Positive Phase 1b ATI-052 Trial Results, Prices $50 Million Offering
27-10-2026
yahoo.com
What is the current price of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The current price of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is $3.97.
ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) since the previous trading day is $-0.02.
ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) since the previous trading day is -0.5013%.
What is the most recent average sentiment score for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The most recent average sentiment score for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The most recent sentiment for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is .
SEC-8K** Filing Available For ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.